Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
Jessica Mandrioli, Roberto D’Amico, Elisabetta Zucchi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders
Fabiola De Marchi, Ivana Munitić, Lea Vidatic, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2793-2793
Open Access | Times Cited: 26
Molecular hallmarks of ageing in amyotrophic lateral sclerosis
Cyril J. Jagaraj, Sina Shadfar, Sara Assar Kashani, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 13
Update on recent advances in amyotrophic lateral sclerosis
Nilo Riva, Teuta Domi, Laura Pozzi, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 4693-4723
Open Access | Times Cited: 12
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis
Kiterie M. E. Faller, Helena Chaytow, Thomas H. Gillingwater
Nature Reviews Neurology (2025) Vol. 21, Iss. 2, pp. 86-102
Closed Access | Times Cited: 1
Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS
Neil A. Shneider, Alex Nesta, Olivia M. Rifai, et al.
NEJM Evidence (2025) Vol. 4, Iss. 5
Closed Access | Times Cited: 1
Pharmacological mTOR inhibitors in ameliorating Alzheimer’s disease: current review and perspectives
Pei-Lun Xie, Meng-Yu Zheng, Ran Han, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Brain-inhabiting bacteria and neurodegenerative diseases: the “brain microbiome” theory
Tarek Ziad Arabi, Aliyah Abdulmohsen Alabdulqader, Belal Nedal Sabbah, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 12
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner
Benjamin J. Murdock, Bangyao Zhao, Kristen D. Pawlowski, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 4
Caloric restriction mimetics improve gut microbiota: a promising neurotherapeutics approach for managing age-related neurodegenerative disorders
Ishika Singh, Shashi Anand, Deepashree J. Gowda, et al.
Biogerontology (2024) Vol. 25, Iss. 6, pp. 899-922
Open Access | Times Cited: 4
Tregs levels and phenotype modifications during Amyotrophic Lateral Sclerosis course
Elisabetta Zucchi, Federico Banchelli, Cecilia Simonini, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Neuroinflammation and Amyotrophic Lateral Sclerosis: Recent Advances in Anti-Inflammatory Cytokines as Therapeutic Strategies
Costanza Stacchiotti, Simona Mazzella di Regnella, Miriam Cinotti, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3854-3854
Open Access
Immunomodulatory effects of calorie restriction and its mimetics: new potential therapeutic approach for autoimmune diseases
Monokesh Kumer Sen, Eileen Liao, Duan Ni, et al.
Pharmacological Reviews (2025), pp. 100063-100063
Closed Access
Rapamycin exerts neuroprotective effects by inhibiting FKBP12 instead of mTORC1 in the mouse model of Parkinson’s disease
Zeyan Zhang, Ziyue Shen, Shiming Xie, et al.
Neuropharmacology (2025), pp. 110504-110504
Closed Access
Astrocyte-mediated inflammatory responses in traumatic brain injury: mechanisms and potential interventions
Haifeng Zhang, Xian Zhang, Yan Chai, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Rapamycin treatment for Alzheimer’s disease and related dementias: a pilot phase 1 clinical trial
Mitzi M. Gonzales, Valentina R. Garbarino, Tiffany F. Kautz, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access
Emerging roles of senolytics/senomorphics in HIV-related co-morbidities
Gagandeep Kaur, Md. Sohanur Rahman, Sadiya Bi Shaikh, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116179-116179
Closed Access | Times Cited: 3
Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial
Giulia Gianferrari, Riccardo Cuoghi Costantini, V. Crippa, et al.
Brain Communications (2024) Vol. 6, Iss. 5
Open Access | Times Cited: 3
Amyotrophic lateral sclerosis as a disease model of sarcopenia
Domenico Azzolino, Rachele Piras, Aı́da Zulueta, et al.
Age and Ageing (2024) Vol. 53, Iss. 9
Closed Access | Times Cited: 3
Novel Prospects in Targeting Neurodegenerative Disorders via Autophagy
Shumayila Khan, Saurabh Upadhyay, Md. Imtaiyaz Hassan
European Journal of Pharmacology (2024) Vol. 984, pp. 177060-177060
Closed Access | Times Cited: 3
Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review
Deepal Gupta, Sunita Vagha, Hitaansh Dhingra, et al.
Cureus (2023)
Open Access | Times Cited: 7
Advances in the regulatory mechanisms of mTOR in necroptosis
Yawen Xie, Guoyu Zhao, Xianli Lei, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis
Xiaoyan Li, Richard Bedlack
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 2, pp. 93-102
Open Access | Times Cited: 2
Advancements and challenges in amyotrophic lateral sclerosis
David Bradford, Kathleen E. Rodgers
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 2
Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis
Elisabetta Pupillo, Elisa Bianchi, Valentina Bonetto, et al.
Brain Behavior and Immunity (2024) Vol. 122, pp. 456-462
Closed Access | Times Cited: 2
Modeling of TDP-43 proteinopathy by chronic oxidative stress identifies rapamycin as beneficial in ALS patient-derived 2D and 3D iPSC models
Valeria Casiraghi, Marta Nice Sorce, Serena Santangelo, et al.
Experimental Neurology (2024) Vol. 383, pp. 115057-115057
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top